Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Cholic acid therapy in Zellweger spectrum disorders

K. Berendse, FC. Klouwer, BG. Koot, EM. Kemper, S. Ferdinandusse, KV. Koelfat, M. Lenicek, FG. Schaap, HR. Waterham, FM. Vaz, M. Engelen, PL. Jansen, RJ. Wanders, BT. Poll-The,

. 2016 ; 39 (6) : 859-868. [pub] 20160728

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18017132
E-zdroje Online Plný text

NLK ProQuest Central od 1999-02-01 do 2018-11-30
Medline Complete (EBSCOhost) od 2009-08-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1999-02-01 do 2018-11-30

Odkazy

PubMed 27469511
DOI 10.1007/s10545-016-9962-9
Knihovny.cz E-zdroje

INTRODUCTION: Zellweger spectrum disorders (ZSDs) are characterized by a failure in peroxisome formation, caused by autosomal recessive mutations in different PEX genes. At least some of the progressive and irreversible clinical abnormalities in patients with a ZSD, particularly liver dysfunction, are likely caused by the accumulation of toxic bile acid intermediates. We investigated whether cholic acid supplementation can suppress bile acid synthesis, reduce accumulation of toxic bile acid intermediates and improve liver function in these patients. METHODS: An open label, pretest-posttest design study was conducted including 19 patients with a ZSD. Participants were followed longitudinally during a period of 2.5 years prior to the start of the intervention. Subsequently, all patients received oral cholic acid and were followed during 9 months of treatment. Bile acids, peroxisomal metabolites, liver function and liver stiffness were measured at baseline and 4, 12 and 36 weeks after start of cholic acid treatment. RESULTS: During cholic acid treatment, bile acid synthesis decreased in the majority of patients. Reduced levels of bile acid intermediates were found in plasma and excretion of bile acid intermediates in urine was diminished. In patients with advanced liver disease (n = 4), cholic acid treatment resulted in increased levels of plasma transaminases, bilirubin and cholic acid with only a minor reduction in bile acid intermediates. CONCLUSIONS: Oral cholic acid therapy can be used in the majority of patients with a ZSD, leading to at least partial suppression of bile acid synthesis. However, caution is needed in patients with advanced liver disease due to possible hepatotoxic effects.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18017132
003      
CZ-PrNML
005      
20180515103232.0
007      
ta
008      
180515s2016 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s10545-016-9962-9 $2 doi
035    __
$a (PubMed)27469511
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Berendse, Kevin $u Department of Pediatric Neurology, Emma Children's Hospital/Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. Laboratory Genetic Metabolic Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
245    10
$a Cholic acid therapy in Zellweger spectrum disorders / $c K. Berendse, FC. Klouwer, BG. Koot, EM. Kemper, S. Ferdinandusse, KV. Koelfat, M. Lenicek, FG. Schaap, HR. Waterham, FM. Vaz, M. Engelen, PL. Jansen, RJ. Wanders, BT. Poll-The,
520    9_
$a INTRODUCTION: Zellweger spectrum disorders (ZSDs) are characterized by a failure in peroxisome formation, caused by autosomal recessive mutations in different PEX genes. At least some of the progressive and irreversible clinical abnormalities in patients with a ZSD, particularly liver dysfunction, are likely caused by the accumulation of toxic bile acid intermediates. We investigated whether cholic acid supplementation can suppress bile acid synthesis, reduce accumulation of toxic bile acid intermediates and improve liver function in these patients. METHODS: An open label, pretest-posttest design study was conducted including 19 patients with a ZSD. Participants were followed longitudinally during a period of 2.5 years prior to the start of the intervention. Subsequently, all patients received oral cholic acid and were followed during 9 months of treatment. Bile acids, peroxisomal metabolites, liver function and liver stiffness were measured at baseline and 4, 12 and 36 weeks after start of cholic acid treatment. RESULTS: During cholic acid treatment, bile acid synthesis decreased in the majority of patients. Reduced levels of bile acid intermediates were found in plasma and excretion of bile acid intermediates in urine was diminished. In patients with advanced liver disease (n = 4), cholic acid treatment resulted in increased levels of plasma transaminases, bilirubin and cholic acid with only a minor reduction in bile acid intermediates. CONCLUSIONS: Oral cholic acid therapy can be used in the majority of patients with a ZSD, leading to at least partial suppression of bile acid synthesis. However, caution is needed in patients with advanced liver disease due to possible hepatotoxic effects.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a žlučové kyseliny a soli $x metabolismus $7 D001647
650    _2
$a bilirubin $x krev $7 D001663
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a kyselina cholová $x krev $x terapeutické užití $7 D019826
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a játra $x metabolismus $7 D008099
650    _2
$a nemoci jater $x farmakoterapie $x metabolismus $7 D008107
650    _2
$a longitudinální studie $7 D008137
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a neutrální endopeptidasa regulující fosfáty $x metabolismus $7 D053402
650    _2
$a transaminasy $x krev $7 D000637
650    _2
$a mladý dospělý $7 D055815
650    _2
$a Zellwegerův syndrom $x krev $x farmakoterapie $x metabolismus $7 D015211
655    _2
$a časopisecké články $7 D016428
700    1_
$a Klouwer, Femke C C $u Department of Pediatric Neurology, Emma Children's Hospital/Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. Laboratory Genetic Metabolic Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
700    1_
$a Koot, Bart G P $u Department of Pediatric Gastroenterology, Emma Children's hospital/ Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
700    1_
$a Kemper, Elles M $u Department of Pharmacy, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
700    1_
$a Ferdinandusse, Sacha $u Laboratory Genetic Metabolic Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
700    1_
$a Koelfat, Kiran V K $u Department of Surgery, Maastricht University, Amsterdam, The Netherlands.
700    1_
$a Lenicek, Martin $u Department of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Schaap, Frank G $u Department of Surgery, Maastricht University, Amsterdam, The Netherlands.
700    1_
$a Waterham, Hans R $u Laboratory Genetic Metabolic Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
700    1_
$a Vaz, Frédéric M $u Laboratory Genetic Metabolic Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
700    1_
$a Engelen, Marc $u Department of Pediatric Neurology, Emma Children's Hospital/Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
700    1_
$a Jansen, Peter L M $u Department of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
700    1_
$a Wanders, Ronald J A $u Laboratory Genetic Metabolic Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
700    1_
$a Poll-The, Bwee Tien $u Department of Pediatric Neurology, Emma Children's Hospital/Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. b.t.pollthe@amc.uva.nl.
773    0_
$w MED00002747 $t Journal of inherited metabolic disease $x 1573-2665 $g Roč. 39, č. 6 (2016), s. 859-868
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27469511 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20180515103406 $b ABA008
999    __
$a ok $b bmc $g 1300756 $s 1013972
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 39 $c 6 $d 859-868 $e 20160728 $i 1573-2665 $m Journal of inherited metabolic disease $n J Inherit Metab Dis $x MED00002747
LZP    __
$a Pubmed-20180515

Najít záznam

Citační ukazatele

Možnosti archivace